Glaukos Corporation
Organization details
- Legal name
- Glaukos Corporation
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 3841 — Surgical & Medical Instruments & Apparatus
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Aliso Viejo
- Headquarters state / province
- California
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- GKOS
- Primary stock exchange
- NYSE
Identifiers
- SEC CIK
- 0001192448
Board of directors
-
Aimee S. Weisner · DirectorSince 2023
-
David F. Hoffmeister · DirectorSince 2023
-
Denice Torres · DirectorSince 2023
-
Gilbert H. Kliman · DirectorSince 2023
-
Leana Wen · DirectorSince 2023
-
Marc Stapley · DirectorSince 2023
-
Mark J. Foley · DirectorSince 2023
-
Thomas William Burns · Director · CHAIRMAN & CEOSince 2023
Chief executives
Director election results
Annual meeting of May 28, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
78.5%
-
95.0%
Board connections
7 of this board's directors also sit on 10 other boards. 8 are in the same sector.
-
STAAR Surgical Company Same sectorvia Aimee S. Weisner and Gilbert H. Kliman
- via David F. Hoffmeister
-
Celldex Therapeutics Inc. Same sectorvia Denice Torres
-
ICU Medical Inc. Same sectorvia David F. Hoffmeister
-
LENSAR Inc. Same sectorvia Aimee S. Weisner
-
Pulmonx Corporation Same sectorvia Thomas William Burns
-
Seaport Therapeutics Inc. Same sectorvia Denice Torres
- via David F. Hoffmeister
-
UroGen Pharma Ltd. Same sectorvia Leana Wen
-
Veracyte Inc. Same sectorvia Marc Stapley
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $80,560,287
- 66 sales by 8 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Nov 4, 2026 | Gilbert H. Kliman Director | Option exercise | +2,500 | $25.77 | $64,425 |
| Nov 4, 2026 | Gilbert H. Kliman Director | Open-market sale | −2,500 | $253.00 | $632,500 |
| Oct 30, 2026 | Navratil Tomas Officer (CHIEF DEVELOPMENT OFFICER) | Option exercise | +4,181 | $55.00 | $229,955 |
| Oct 30, 2026 | Aimee S. Weisner Director | Gift | −2,382 | — | — |
| Oct 30, 2026 | Navratil Tomas Officer (CHIEF DEVELOPMENT OFFICER) | Option exercise | +8,788 | $85.94 | $755,241 |
| Oct 30, 2026 | Aimee S. Weisner Director | Gift | +2,382 | — | — |
| Oct 30, 2026 | Navratil Tomas Officer (CHIEF DEVELOPMENT OFFICER) | Open-market sale | −10,221 | $237.54 | $2,427,896 |
| Oct 30, 2026 | Navratil Tomas Officer (CHIEF DEVELOPMENT OFFICER) | Open-market sale | −12,836 | $238.56 | $3,062,156 |
| Oct 30, 2026 | Navratil Tomas Officer (CHIEF DEVELOPMENT OFFICER) | Open-market sale | −14,943 | $239.64 | $3,580,941 |
| Oct 30, 2026 | Navratil Tomas Officer (CHIEF DEVELOPMENT OFFICER) | Open-market sale | −6,436 | $240.52 | $1,547,987 |
| Oct 5, 2026 | Navratil Tomas Officer (CHIEF DEVELOPMENT OFFICER) | Open-market sale | −888 | $163.93 | $145,570 |
| Oct 5, 2026 | Navratil Tomas Officer (CHIEF DEVELOPMENT OFFICER) | Open-market sale | −327 | $164.78 | $53,883 |
| Oct 5, 2026 | Navratil Tomas Officer (CHIEF DEVELOPMENT OFFICER) | Open-market sale | −312 | $165.60 | $51,667 |
| Sep 25, 2026 | Navratil Tomas Officer (CHIEF DEVELOPMENT OFFICER) | Open-market sale | −167 | $151.70 | $25,334 |
| Sep 25, 2026 | Navratil Tomas Officer (CHIEF DEVELOPMENT OFFICER) | Open-market sale | −136 | $152.71 | $20,769 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Glaukos Corporation
Who is the CEO of Glaukos Corporation?
Thomas William Burns is Glaukos Corporation's CHAIRMAN & CEO.
How many directors are on Glaukos Corporation's board?
Glaukos Corporation's board has 8 directors: Aimee S. Weisner, David F. Hoffmeister, Denice Torres, Gilbert H. Kliman, Leana Wen, Marc Stapley, Mark J. Foley and Thomas William Burns.
Are Glaukos Corporation insiders buying or selling shares?
Over the last 12 months, Glaukos Corporation insiders made no open-market purchases and sold $80.6 million of shares in 66 sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="glaukos-corporation"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.